GeneLink Launches Dermagenetics® to Spa Industry and Appoints Dr. Robert Keller to its Medical Advisory Board 
October 7, 2004

MARGATE, NJ, October 7, 2004 – GeneLink BioSciences, Inc. (OTCBB:GNLK) the genetic biosciences company announced it has entered into an agreement with Robert P.K. Keller, M.D. to help launch its Dermagenetics® system of tests and products to the spa industry and to serve on GeneLink’s Medical Advisory Board. Dr. Keller is Founder and Medical Director of The Keller Skin & Body Institute, as well as Chief Medical Officer for Pebble Beach Resorts. He will coordinate the promotion of GeneLink’s Dermagenetics® technologies – a proprietary system of genetic tests that enables customized anti-wrinkle and skin-care formulations.

Dr. Keller began his distinguished career in medicine over 30 years ago and has been a respected member of the Monterey Peninsula medical community for 21 years. Residency trained as a trauma physician and surgeon, he began repairing damaged skin in the late 1970’s. Wanting to become more proactive in skin repair, he took post-doctorate studies in cosmetic and anti-aging medicine and trained with some of the world’s most renowned physicians. A former nationally syndicated television medical news commentator, Dr. Keller has lectured internationally and is listed in the 2001 National Registry of Who’s Who. His patient list includes many of the most celebrated names in sports, entertainment and business.

“As one of the first medispas in the country, the Keller Skin & Body Institute at Pebble Beach Resorts has experience with customized retail products,” says Dr. Keller. “But when the Resorts’ Board of directors includes Clint Eastwood, Arnold Palmer, Peter Uberov and Dick Ferris, you can’t afford to make mistakes.” He adds, “After researching Dermagenetics®, we brought the system to our Institute and it has been an instant success. By introducing Dermagenetics® to our clients we have continued to distinguish our spa as a leader in new treatments. This in turn has lead to increased revenue streams and profitability. The only question remaining is ‘what’s next’ from GeneLink?”

John R. DePhillipo, GeneLink Chairman says, “We are excited and proud to welcome such a dignified member of the medical community to our team; his experience and expertise will play an important role in our plans to market our genetic tests and matching skin-care products to the international spa industry.” DePhillipo adds, “With more than a decade of 15% annual growth and 2003 total revenues exceeding $11.1 billion, medical and day spas represent the 4th largest leisure industry in the U.S. – GeneLink’s Dermagenetics® products promise to be the next generation profit center for this fast growing industry.”

GeneLink has developed a proprietary method for "genetic profiling" (patents pending) and is licensing this breakthrough technology to companies that market or manufacture products for the $100 billion plus nutritional supplement, skin care and wellness industries.

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE:GeneLink BioSciences, Inc.